Research Topics
| ANNETTE FLECKENSTEINSummaryAffiliation: University of Utah Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Differential effects of stimulants on monoaminergic transporters: pharmacological consequences and implications for neurotoxicityA E Fleckenstein
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Rm 201, Salt Lake City, UT 84112, USA
Eur J Pharmacol 406:1-13. 2000..Hence, this review will describe recent ex vivo studies investigating the rapid and differential affects of several stimulants on both plasmalemmal and vesicular monoamine transporter function...- New insights into the mechanism of action of amphetaminesAnnette E Fleckenstein
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
Annu Rev Pharmacol Toxicol 47:681-98. 2007..All of these mechanisms have potential implications for both amphetamine- and methamphetamine-induced neurotoxicity, as well as dopaminergic neurodegenerative diseases... 
Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposureLisa M McFadden
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
J Pharmacol Exp Ther 340:295-303. 2012..Taken together, these results may provide insight into the neurochemical deficits reported in human METH abusers...- Impact of psychostimulants on vesicular monoamine transporter functionAnnette E Fleckenstein
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
Eur J Pharmacol 479:283-9. 2003..As described in this review, these studies not only provide insight into the pharmacological actions of stimulants, but also mechanisms underlying neurodegenerative disorders, including Parkinson's disease... - 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuseGregory C Hadlock
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
J Pharmacol Exp Ther 339:530-6. 2011..These data demonstrate that mephedrone has a unique pharmacological profile with both abuse liability and neurotoxic potential... - A single methamphetamine administration rapidly decreases vesicular dopamine uptakeJeffrey M Brown
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
J Pharmacol Exp Ther 302:497-501. 2002..These studies provide further evidence that psychostimulants rapidly and differentially modify vesicular DA uptake. In addition, these studies demonstrate a complex role for D(2) DA receptors in altering vesicular DA transport... - Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicityJannine G Truong
University of Utah, Salt Lake City, 84112, USA
J Pharmacol Exp Ther 314:1087-92. 2005..Implications with regard to methamphetamine-induced dopaminergic deficits, as well as dopamine-associated neurodegenerative disorders such as Parkinson's disease, are discussed... - Bupropion increases striatal vesicular monoamine transportKristi S Rau
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
Neuropharmacology 49:820-30. 2005..The findings from this study demonstrate similarities and differences in the mechanism by which MPD and bupropion affect striatal dopaminergic nerve terminals... - Measurement of kinetically resolved vesicular dopamine uptake and efflux using rotating disk electrode voltammetryTrent J Volz
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
J Neurosci Methods 155:109-15. 2006.... - Methamphetamine administration reduces hippocampal vesicular monoamine transporter-2 uptakeKristi S Rau
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Rm. 201, Salt Lake City, UT 84112, USA
J Pharmacol Exp Ther 318:676-82. 2006..These findings suggest a link between METH-induced alterations in serotonergic hippocampal vesicular uptake and the persistent hippocampal serotonergic deficits induced by the stimulant... - Kinetic analysis of developmental changes in vesicular monoamine transporter-2 functionTrent J Volz
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, 84112, USA
Synapse 60:474-7. 2006..PND 88-92 rats. However, decreased VMAT-2 density in PND 38-42 rats reduces V(max), which in turn lowers DA uptake... - Tolerance to the neurotoxic effects of methamphetamine in young ratsEvan L Riddle
University of Utah, Department of Pharmacology and Toxicology, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
Eur J Pharmacol 435:181-5. 2002..The methamphetamine biweekly pretreatment attenuated the hyperthermia caused by the neurotoxic methamphetamine regimen; a phenomenon that may have contributed to the neuroprotection... - Persistence of tolerance to methamphetamine-induced monoamine deficitsJonathan P Danaceau
Center for Human Toxicology, University of Utah, UT 84112, USA
Eur J Pharmacol 559:46-54. 2007.... - Methamphetamine-induced alterations in monoamine transport: implications for neurotoxicity, neuroprotection and treatmentTrent J Volz
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
Addiction 102:44-8. 2007..To review studies delineating the neurotoxic effects of methamphetamine on monoamine transport in dopaminergic neurons of the striatum and nucleus accumbens... - Therapeutic doses of amphetamine and methylphenidate selectively redistribute the vesicular monoamine transporter-2Evan L Riddle
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
Eur J Pharmacol 571:25-8. 2007..These data represent the first report that amphetamine redistributes VMAT-2 protein. In addition, these data demonstrate that the trafficking of VMAT-2 after amphetamine or methylphenidate is selective for monoaminergic neurons... - Methylphenidate administration alters vesicular monoamine transporter-2 function in cytoplasmic and membrane-associated vesiclesTrent J Volz
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
J Pharmacol Exp Ther 323:738-45. 2007.... - Methylphenidate-induced increases in vesicular dopamine sequestration and dopamine release in the striatum: the role of muscarinic and dopamine D2 receptorsTrent J Volz
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
J Pharmacol Exp Ther 327:161-7. 2008.... - Differential regional effects of methamphetamine on dopamine transportPei Wen Chu
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
Eur J Pharmacol 590:105-10. 2008.... - Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicityJ Paul Hansen
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
J Pharmacol Exp Ther 300:1093-100. 2002..Taken together, these results reveal several differences between effects of MDMA and previously reported METH on DAT and VMAT-2; differences that may underlie the dissimilar neurotoxic profile of these agents... - Dopamine D2 receptor activation increases vesicular dopamine uptake and redistributes vesicular monoamine transporter-2 proteinJannine G Truong
University of Utah, Salt Lake City, UT 84112, USA
Eur J Pharmacol 504:27-32. 2004..Taken together, these data demonstrate that dopamine D2 receptor subtype activation increases vesicular dopamine uptake. Implications of this phenomenon with regard to the treatment of Parkinson's disease will be discussed... - Differential trafficking of the vesicular monoamine transporter-2 by methamphetamine and cocaineEvan L Riddle
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Rm. 201 84112, Salt Lake City, UT 84112, USA
Eur J Pharmacol 449:71-4. 2002..These data suggest that psychostimulants acutely and differentially affect VMAT-2 subcellular localization... - Methylphenidate redistributes vesicular monoamine transporter-2: role of dopamine receptorsVeronica Sandoval
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
J Neurosci 22:8705-10. 2002..These observations suggest a role for DA in the MPD-induced redistribution of VMAT-2. The implications of this phenomenon will be discussed... - Inhibitory effect of reserpine on dopamine transporter functionRyan R Metzger
Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City 84112, USA
Eur J Pharmacol 456:39-43. 2002..Taken together, these data suggest that reserpine may transiently alter dopamine transporter function in a noncompetitive, indirect manner... - Ceramide-induced alterations in dopamine transporter functionEvan L Riddle
Department of Pharmacology and Toxicology, University of Utah, Room 201, 30 South 2000 East, Salt Lake City, UT 84112, USA
Eur J Pharmacol 458:31-6. 2003..e., which presumably competes for uptake with 5-HT). Taken together, these results reveal that ceramide is a novel modulator of monoamine transporter function, and may alter the affinity of dopamine transporters for its primary substrate... - Methylphenidate alters vesicular monoamine transport and prevents methamphetamine-induced dopaminergic deficitsVeronica Sandoval
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
J Pharmacol Exp Ther 304:1181-7. 2003..These findings not only provide insight into the neurotoxic effects of methamphetamine but also mechanisms underlying dopamine neurodegenerative disorders, including Parkinson's disease... - Methamphetamine rapidly decreases mouse vesicular dopamine uptake: role of hyperthermia and dopamine D2 receptorsYvette V Ugarte
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Room 201, Salt Lake City, UT 84112, USA
Eur J Pharmacol 472:165-71. 2003..Unlike methamphetamine, the dopamine reuptake inhibitors, methylphenidate and cocaine, rapidly increased vesicular dopamine uptake. The implications of these phenomena are discussed... - Pramipexole increases vesicular dopamine uptake: implications for treatment of Parkinson's neurodegenerationJannine G Truong
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
Eur J Pharmacol 474:223-6. 2003..The implications of this finding relevant to the treatment of neurodegenerative disorders are discussed... - Psychostimulants and vesicle trafficking: a novel mechanism and therapeutic implicationsGlen R Hanson
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
Ann N Y Acad Sci 1025:146-50. 2004.... - The methamphetamine experience: a NIDA partnershipGlen R Hanson
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Room 112, Salt Lake City, UT 84112, USA
Neuropharmacology 47:92-100. 2004.... - Apomorphine increases vesicular monoamine transporter-2 function: implications for neurodegenerationJannine G Truong
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
Eur J Pharmacol 492:143-7. 2004..This effect of apomorphine on vesicular dopamine uptake was blocked by pretreating with eticlopride, a dopamine D2 receptor antagonist. The implications of these findings relevant to the treatment of neurodegeneration are discussed... - Methamphetamine increases dopamine transporter higher molecular weight complex formation via a dopamine- and hyperthermia-associated mechanismAnthony J Baucum
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
J Neurosci 24:3436-43. 2004..The implications of this phenomenon with regard to the neurotoxic potential of these stimulants are discussed... - Age-dependent effects of methamphetamine on VMAT-2Kristi S Rau
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Skaggs Hall, Room 201, Salt Lake City, UT 84112, USA
Ann N Y Acad Sci 1074:154-9. 2006.... - Role of monoamine transporters in mediating psychostimulant effectsEvan L Riddle
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
AAPS J 7:E847-51. 2005.... - Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamineKamisha L Johnson-Davis
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112-9457, USA
J Pharmacol Exp Ther 309:578-86. 2004..In summary, these data are the first to demonstrate an association between the prevention of acute alterations in vesicular dopamine uptake and the development of tolerance to the neurotoxic effects of methamphetamine... - Mechanisms of methamphetamine-induced dopaminergic neurotoxicityEvan L Riddle
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, Utah 84112, USA
AAPS J 8:E413-8. 2006..This review will describe the current understanding of how high-dose METH administration leads to the production of these toxic reactive species and consequent permanent dopaminergic deficits... - The role of the plasmalemmal dopamine and vesicular monoamine transporters in methamphetamine-induced dopaminergic deficitsTrent J Volz
Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA
J Neurochem 101:883-8. 2007.... - The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicityKamisha L Johnson-Davis
Department of Pharmacology and Toxicology, University of Utah, 20 South 2030 East, Room 490, Salt Lake City, UT 84112-9457, USA
Eur J Pharmacol 482:151-4. 2003..These data differ from previous findings thereby highlighting that different mechanisms contribute to the tolerance of the neurotoxic effects... - Phencyclidine increases vesicular dopamine uptakeMichael J Crosby
Department of Pharmacology and Toxicology, University of Utah, 30 South 2000 East, Salt Lake City, UT 84112, USA
Eur J Pharmacol 438:75-8. 2002..These data demonstrate a heretofore unreported mechanism that may contribute to the ability of PCP to influence dopamine neuronal function and exert its pharmacological effects...
Research Grants
- K02 ApplicationANNETTE FLECKENSTEIN; Fiscal Year: 2007This is a Career Development Award proposal for Dr. Annette Fleckenstein. She is an Associate Professor of Pharmacology and Toxicology at the University of Utah...
- Psychostimulants and Monoamine TransportersANNETTE FLECKENSTEIN; Fiscal Year: 2009....
- DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINESANNETTE FLECKENSTEIN; Fiscal Year: 2009..This, in turn, may enhance understanding of a variety of DAT-associated disorders ranging from stimulant abuse to neurodegenerative diseases such as Parkinson's disease. ..
- Psychostimulants and Monoamine TransportersANNETTE FLECKENSTEIN; Fiscal Year: 2010....
- DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINESANNETTE FLECKENSTEIN; Fiscal Year: 2007..This, in turn, may enhance understanding of a variety of DAT-associated disorders ranging from stimulant abuse to neurodegenerative diseases such as Parkinson's disease. ..
- Psychostimulants and Monoamine TransportersANNETTE FLECKENSTEIN; Fiscal Year: 2007..Finally, these studies will advance our understanding of a wide array of processes including those underlying addiction and those contributing to the development of DA neurodegenerative diseases. ..
- DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINESANNETTE FLECKENSTEIN; Fiscal Year: 2004..The mechanism and selectivity of this phenomenon will be studied. ..
- DRUG ABUSE AND REGULATORY ENZYMES OF BIOGENIC AMINESANNETTE FLECKENSTEIN; Fiscal Year: 2010..This, in turn, may enhance understanding of a variety of DAT-associated disorders ranging from stimulant abuse to neurodegenerative diseases such as Parkinson's disease. ..